Overview

Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy

Status:
Completed

Trial end date:
2017-11-02

Target enrollment:

Participant gender:

Summary

This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Medivation, Inc.
Pfizer

Collaborators:

Astellas Pharma Inc
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Treatments:

Docetaxel